Lenalidomide Capsule
Product Images NDC 31722-261

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Lenalidomide (NDC 31722-261). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

10-container (10 Container)

Label for Lenalidomide Capsules 10 mg by Camber Pharmaceuticals, Inc. The label indicates the product contains 100 capsules, with a warning about potential human birth defects. Storage instructions and a medication guide URL are provided. The label includes a barcode and manufacturing information showing production by Hetero Labs Limited in India for Camber Pharmaceuticals in Piscataway, NJ.*

FDA Label Image

15-container (15 Container)

Lenalidomide Capsules 15 mg oral dosage form by Camber Pharmaceuticals, Inc. The label indicates the package contains 100 capsules. The label includes a warning about potential human birth defects and storage instructions. Manufacturer details and contact information are provided, along with a barcode and reference to the medication guide availability online.*

FDA Label Image

2-5container (2 5 Container)

Label for Lenalidomide Capsules 2.5 mg by Camber Pharmaceuticals, Inc. The label includes the NDC 31722-257-28, instructions for pharmacists, a warning about potential human birth defects, storage conditions, and a contact number. The package contains 28 capsules for oral use.*

FDA Label Image

20-container (20 Container)

Label for Lenalidomide Capsules 20 mg by Camber Pharmaceuticals, Inc. The label includes warnings about potential human birth defects, storage instructions, a pharmacist note, and a U.S. contact number. The package contains 100 capsules and provides a URL for medication guides. Manufacturer details and barcode are visible.*

FDA Label Image

25-container (25 Container)

Packaging label for Lenalidomide Capsules 25 mg by Camber Pharmaceuticals, Inc. The label includes dosage information indicating each capsule contains 25 mg of lenalidomide. It states a package size of 100 capsules, with storage instructions and a warning about potential human birth defects. Contact information and manufacturer details are also present.*

FDA Label Image

5-container (5 Container)

Label for Lenalidomide Capsules 5 mg by Camber Pharmaceuticals, Inc. The label states it contains 100 capsules. It includes dosage storage instructions, a warning about potential human birth defects, and contact information. The label also identifies Hetero Labs Limited, India, as the manufacturer.*

FDA Label Image

Camber (Camber)

FDA Label Image

Figure-1 (Figure 1)

A Kaplan-Meier survival curve graph showing progression free survival (months) on the x-axis and survival probability (%) on the y-axis. The graph compares three groups labeled Rd Continuous (blue solid line), Rd18 (green dashed line), and MPT (red dash-dot line). The graph includes confidence intervals, p-values, and a table of the number of subjects at risk over time for each group.*

FDA Label Image

Figure-2 (Figure 2)

Kaplan-Meier survival probability curve comparing overall survival in months for three treatment groups: Rd Continuous, Rd18, and MPT. The chart includes survival probability percentages on the y-axis and time in months on the x-axis, with data tables showing numbers of subjects at risk and hazard ratios with confidence intervals for the comparisons.*

FDA Label Image

Figure-3 (Figure 3)

A Kaplan-Meier survival curve comparing progression-free survival over months between Lenalidomide and placebo groups. The graph shows higher survival probability for Lenalidomide (blue solid line) than placebo (red dashed line). Below the plot is a table indicating the number of subjects at risk over time and PFS event rates for both groups.*

FDA Label Image

Figure-4 (Figure 4)

A Kaplan-Meier curve chart showing progression-free survival over months comparing Lenalidomide to placebo. The X-axis represents progression-free survival in months, and the Y-axis shows survival probability. Two survival curves are shown: Lenalidomide (solid blue line) and placebo (dashed red line). The chart includes the number of subjects at risk at various time points and hazard ratio with confidence intervals comparing Lenalidomide to placebo.*

FDA Label Image

Figure-5 (Figure 5)

A Kaplan-Meier survival curve graph depicting time to progression in months on the x-axis and proportion of subjects on the y-axis. It compares two treatment groups: Lenalidomide/Dex and Placebo/Dex. The graph includes a hazard ratio (HR) of 0.285 with a 95% confidence interval and a significant log-rank p-value less than 0.001.*

FDA Label Image

Figure-6 (Figure 6)

A Kaplan-Meier survival curve chart showing the proportion of subjects over time to progression in months. The chart compares two groups: Lenalidomide/Dex and Placebo/Dex, illustrating differences in progression rates over a 25-month period with statistical data including hazard ratio and p-value.*

FDA Label Image

Figure-7 (Figure 7)

A progression-free survival Kaplan-Meier curve comparing survival probability over time (in months) between two groups: one receiving Rituximab plus Lenalidomide and the other Rituximab plus placebo. The chart includes a risk table showing the number of subjects at risk at various time points up to 48 months, with survival probabilities declining over time for both groups.*

FDA Label Image

Lenalidomidestructure (Lenalidomidestructure)

Chemical structure of lenalidomide, showing its molecular arrangement with an amino group attached to a bicyclic structure and a lactam ring.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.